Protein Expression Market Size, Share, Opportunities, And Trends By Expression System (Prokaryotic, Mammalian Cell, Insect Cell, Yeast, Others), By Product (Reagents, Competent Cells, Expression Vectors, Services, Instruments), By Application (Therapeutic, Industrial, Research), And By Geography - Forecasts From 2023 To 2028

The protein expression market is anticipated to grow at a steady pace throughout the forecast period.  Protein expression refers to the process by which a gene's information is used to synthesize a specific protein. The process of protein expression involves converting the genetic code in the DNA into functional proteins that carry out various cellular functions. The advancements in genetic engineering and proteomics are major growth drivers of the protein expression market. Moreover, the expanding biopharmaceutical industry along with the increasing focus on rare diseases and drug development is further expected to augment the protein expression market. 

Advancements in Genetic Engineering

Advancements in genetic engineering techniques, such as CRISPR-Cas9, have enhanced the ability to engineer cell lines for improved protein expression. The CRISPR-Cas9 gene editing technology allows precise and efficient editing of specific DNA sequences, making it easier to add, delete, or modify genes in a wide range of organisms.  These growing technological advancements are major growth drivers of the protein expression market. For instance, Kytopean launched an early access program for the gene delivery platform ‘Flowfect Discover’ in January 2023. The platform enables the delivery of complex genetic engineering materials with enhanced precision and efficiency. Moreover, advances in DNA synthesis technologies have made it easier and more affordable to create custom DNA sequences.

Expanding Biopharmaceutical Industry

The expansion of the biotechnology industry and the increasing adoption of biologics by pharmaceutical companies have positively contributed to the growth of the protein expression market. Rapid developments in biotechnology, including genetic engineering, recombinant DNA technology, and protein expression systems, have paved the way for the production of novel biopharmaceuticals. Various collaborations are expanding the biopharmaceutical industry thereby aiding the protein expression market. For instance, In September 2022, CytoReason and Pfizer entered into an extended collaboration agreement to utilize artificial intelligence (AI) in drug discovery and development initiatives. The collaboration is expected to continue for the next five years. 

Increasing Focus on Rare Diseases

The pharmaceutical industry has placed a strong emphasis on the development of orphan medications for rare Diseases. The protein expression market is expected to boost as many of these medications are protein-based therapies and thus need specialized protein molecules. According to recent data from the Genetic and Rare Diseases Information Center, around 30 million Americans are impacted by rare diseases. Therefore, the focus on treatment for rare diseases is growing. For example, the Rare Diseases Clinical Research Network program by NIH aims to accelerate medical research on rare diseases by promoting collaboration, facilitating enrollment in studies, and fostering data sharing among researchers.

Advances in Proteomics 

Advances in proteomics have significantly transformed our understanding of proteins and their roles in various biological processes thereby propelling the protein expression market. For example, Modern mass spectrometry techniques, such as tandem mass spectrometry (MS/MS) and liquid chromatography-mass spectrometry (LC-MS), enable the sensitive and high-throughput study of proteins. Techniques like X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and cryo-electron microscopy (cryo-EM) allow researchers to determine protein structures at high resolutions, unveiling critical insights into protein interactions and mechanisms. Further, integrating proteomics with genomics and transcriptomics data has enabled comprehensive analyses of cellular processes. Multi-omics approaches provide a holistic view of gene expression regulation and molecular interactions within biological systems.

Restraints in the Market

The protein expression market has experienced growth and development however some restraints or challenges can impact its expansion. For example, setting up and maintaining protein expression systems can be expensive. The high initial investment can deter smaller research organizations or companies with limited budgets from adopting protein expression technologies. Eukaryotic proteins, especially those requiring extensive post-translational modifications, may not be adequately expressed or processed in prokaryotic expression systems like bacteria. This limitation necessitates more complex and time-consuming eukaryotic expression systems. Additionally, the protein expression market faces intense competition, as numerous well-established companies strive for market share making it challenging for new entrants. 

North America is Largest Expanding Market

North America is expected to hold a significant share of the protein expression market during the forecast period. The factors attributed to such a share are strong healthcare infrastructure, increasing R&D in healthcare, increasing usage of protein technologies, and the growing burden of chronic disease. For instance, healthcare spending in the United States remains significantly higher, both per capita and as a percentage of its Gross Domestic Product (GDP), compared to other high-income nations as per the Commonwealth Foundation 2020 report.  Moreover, the expanding pharmaceutical industry further augments the protein expression market in the region. For instance, the contribution of the pharmaceutical sector to Canada’s GDP increased by almost $1 billion in 2020 as per the National Statistical Office, Canada. 

Major Market Players

• Agilent Technologies, Inc. is a prominent multinational corporation that focuses on serving the life sciences, diagnostics, and applied chemical industries on a global scale. It offers instruments, software, consumables, and services used for applications such as genomics, proteomics, metabolomics, and environmental analysis.
• Thermo Fisher Scientific, Inc. offers a wide range of products and services to support life sciences research. It offers solutions for genomics, proteomics, cell culture, and other applications. It offers Expi293 Expression system, ExpiCHO, Expression system, ExpiSF Expression system, and GeneArt Protein Expression System as a part of recombinant protein expression systems. 
• Merck Millipore offers a comprehensive portfolio of products and services designed to support research and development in life sciences such as drug discovery, cell culture, genomics, proteomics, and analytical testing. 

Key Market Developments

• In July 2023, Lonza launched the TheraPRO® CHO Media System to optimize productivity and protein quality when used with the GS-CHO cell line. It supports pharmaceutical and biotechnology companies involved in the manufacturing of therapeutic proteins to further improve product quality. 
• In May 2023, to broaden the range of spatial analysis capabilities offered by Visium CytAssist, 10x Genomics introduced the Visium CytAssist Gene and Protein Expression Assay. This new assay is designed to enhance the scope and utility of spatial analysis in studying gene and protein expression patterns. 
• In March 2022, ProteoGenix launched XtenCHO™ Transient Expression System to exhibit properties that maximize protein production yields. It speeds up the early stages of drug screening and simplifies the manufacturing of recombinant proteins. 

Segmentation:

• By Expression System
  • Prokaryotic
  • Mammalian Cell
  • Insect Cell
  • Yeast
  • Others
• By Product
  • Reagents
  • Competent Cells
  • Expression Vectors
  • Services
  • Instruments
• By Application
  • Therapeutic
  • Industrial
  • Research
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • The Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

1.  INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. PROTEIN EXPRESSION MARKET, BY EXPRESSION SYSTEM

5.1. Introduction

5.2. Prokaryotic

5.3. Mammalian Cell

5.4. Insect Cell

5.5. Yeast

5.6. Others

6. PROTEIN EXPRESSION MARKET, BY PRODUCT

6.1. Introduction

6.2. Reagents

6.3. Competent Cells

6.4. Expression Vectors

6.5. Services

6.6. Instruments

7. PROTEIN EXPRESSION MARKET, BY APPLICATION

7.1. Introduction

7.2. Therapeutic

7.3. Industrial

7.4. Research

8. PROTEIN EXPRESSION MARKET, BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

10.1. Agilent Technologies, Inc.

10.2. Bio-Rad Laboratories

10.3. Thermo Fisher Scientific, Inc.

10.4. Merck Millipore (Merck KGaA) 

10.5. New England BioLabs, Inc.

10.6. Promega Corporation

10.7. QIAGEN

10.8. Takara Bio, Inc.

10.9. Oxford Expression Technologies

10.10. Lucigen Corporation

Agilent Technologies, Inc.

Bio-Rad Laboratories

Thermo Fisher Scientific, Inc.

Merck Millipore (Merck KGaA) 

New England BioLabs, Inc.

Promega Corporation

QIAGEN

Takara Bio, Inc.

Oxford Expression Technologies

Lucigen Corporation